The Clinical Value Of CT7 Expression In Patients With Multiple Myeloma

Background:Multiple myeloma (MM) is a hematologic malignancy, which is characterized by extensive bone damage,anemia and renal failure. Multiple myeloma still a life-threatening disease and the key targets or factors on its development are needed. Cancer testis antigen 7 (CT7) is a crucial member of cancer testis antigens (CTAs) family, which is frequently expressed in MM patients with high-intensity, and might be used in the evaluation and treatment of myeloma.Objective:(1) To investigate relationship between the expression of CT7 and the stage and clinical indexes of MM(2) To investigate the different expression of CT7 in newly diagnosed patients with multiple myeloma and those in different remission status(3) To investigate the different response to bortezomib in multiple myeloma patients who with the expression of CT7 or notMethods:We collected bone marrow mononuclear cells and biopsy samples from MM patients in different stages and different remission status. And the expression levels of CT7 was detected with qPCR and IHC. At the same time,we should collect the clinical data of these patients. At last, we analysis those data we collected with SPSS.Results:(1)In this study, we collected 80 patients with MM. The patients’ average age is 61.01±10.887 years old, and the male to female ratio is 40/40. In these patients, IgG represented the most common idiotype with 33 cases, and 24 cases with IgA,16 cases with light chain and seven cases with other rare types. We collected 111 samples. In these samples,43 BM samples were from primal MM patients,68 from previously treated patients.(2) The positive rate with the expression of CT7 in MM patients with was 72.97% (81/111), with 79.1%(68/86) in qPCR and 54.3%(19/35) in IHC. And the expression of CT7 in mRNA was dependent of the proportion of plasma cells and M protein(r=0.345、 0.409,p<0.01). The expression of CT7 in mRNA was correlation with β2-MG and ISS stage (p<0.05). The expression of CT7 in protein was correlation with the proportion of plasma cells and remission stage.(3)The positive rate with the expression of CT7 in protein was significantly higher in those patients who didn’t achieve remission after treatment than those who achieved remission(88.3%、80.0% vs 10.0%,p=0.02).(4)In those newly diagnosed MM patients with follow-up, we observed significantly higher remission rate in those patients without CT7 expression(p=0.02). But in the 23 patients who treated by bortezomib, we didn’t found significant difference remission rates in those with expression of CT7 or not(84.2% vs 100%, p=0.266).Conclusion:In the study, we found that CT7 gene is widely expressed in multiple myeloma patients, and the expression of CT7 was associated with the proportion of plasma cells and M protein. In the no-remission and relapse patients, the positive rate of CT7 expression was significantly higher. It suggested that CT7 may indicate a poor prognosis Now the efficacy of bortezomib for multiple myeloma is worthy of recognition. We found treatment with bortezomib could improve the poor prognosis of CT7, but further study was needed to research the specific mechanism.